NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ULTRAM ER (tramadol hydrochloride) by Bausch + Lomb is mechanism of action ultram er is a centrally acting synthetic opioid analgesic. Approved for pain, low back pain, osteoarthritis and 1 more indications. First approved in 2005.
Drug data last refreshed Yesterday
Mechanism of Action
Mechanism of Action ULTRAM ER is a centrally acting synthetic opioid analgesic. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to µ-opioid receptors and weak inhibition of…
Worked on ULTRAM ER at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.